Effects of K+-canrenoate on the development of DOCA-salt hypertension.
The effects of K+-canrenoate, a digoxin antagonist, on the role of digoxin-like factor in the development of DOCA-salt hypertension has been examined. DOCA-salt rats treated with 66 mg kg-1 day-1 of K+-canrenoate (s.c.) presented a lower increase in blood pressure (P less than 0.01), less cardiac hypertrophy (P less than 0.05) and hypokalaemia (P less than 0.05) than non-treated DOCA-salt rats. K+-canrenoate treatment did not lead to significant changes in urinary volume, Na+ and K+ urinary excretion or suppression of plasma renin activity in DOCA-salt rats. None of the parameters were significantly different between uninephrectomized-salt rats treated or non-treated with K+-canrenoate. These data suggest a role for digoxin-like factor in DOCA-salt hypertension. However, the non-normalization of blood pressure observed in K+-canrenoate DOCA-salt treated rats indicates that other factors contribute to the initiating mechanisms in this type of hypertension. Moreover, these data suggest that digoxin-like factor plays no role in the suppression of plasma renin activity induced by DOCA and salt treatment.
Vargas
F
F
Department of Biochemistry, Faculty of Medicine, University of Granada, Spain.
Haro
J M
JM
Jodar
E
E
Soler
A
A
Garcia del Rio
C
C
D000818:Animals; D001794:Blood Pressure / Q000187:drug effects; D001835:Body Weight / Q000187:drug effects; D002191:Canrenoic Acid / Q000494:pharmacology*; D003900:Desoxycorticosterone; D006339:Heart Rate / Q000187:drug effects; D006973:Hypertension / Q000139:chemically induced / Q000517:prevention & control*; D008297:Male; D009318:Natriuresis / Q000187:drug effects; D009929:Organ Size / Q000187:drug effects; D011188:Potassium / Q000097:blood; D011245:Pregnadienes / Q000494:pharmacology*; D051381:Rats; D011919:Rats, Inbred Strains; D013997:Time Factors
D011245:Pregnadienes; D003900:Desoxycorticosterone; D002191:Canrenoic Acid; D011188:Potassium